Posted by Michael Wonder on 01 Jul 2021
U.S. FDA accepts filing of Hutchmed's NDA for surufatinib for the treatment of advanced neuroendocrine tumours
1 July 2021 - U.S. FDA has assigned a target action date of 30 April 2022.
Hutchmed today announces that the U.S. FDA has accepted its filing of the new drug application for surufatinib for the treatment of pancreatic and extra-pancreatic (non-pancreatic) neuroendocrine tumours.
